Abstract
Delayed cutaneous reactions occur in up to 24% of patients receiving mogamulizumab for cutaneous T-cell lymphoma (CTCL). This ‘mogamulizumab-associated rash’ is the most common adverse event leading to mogamulizumab discontinuation. Safe and effective methods to reintroduce mogamulizumab would allow continued treatment with this potentially life-saving medication. We present 2 patients with mogamulizumab-associated rash who were able to receive mogamulizumab via outpatient desensitization without rash recurrence.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
